RxDoctor Payments Data

Chad Phillips

Psychiatric/Mental Health · Knoxville, TNNPI 1992190359

Payments from drug & device makers

$4,557in general payments, 2019–2025

Across 202 payments — averaging $22.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$698
  • Supernus Pharmaceuticals, Inc.$668
  • Axsome Therapeutics, Inc.$294
  • Lundbeck LLC$281
  • Neurocrine Biosciences, Inc.$242
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$4,51099%
  • Education$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,557 in reported general payments places this provider in the 85th percentile of 1,167 psychiatric/mental health providers in Tennessee.

See all psychiatric/mental health providers in Tennessee

Medicare billing

Part B allowed, 2024
$5,729
Medicare patients
11
Services billed
78

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Abilify MaintenaAripiprazole13$36,070
Duloxetine Hcl34$771
Bupropion XlBupropion Hcl14$633
Lurasidone Hcl11$489
Lorazepam24$283
Gabapentin20$239
Quetiapine Fumarate21$202
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine11$200
Alprazolam ErAlprazolam22$192
Methylphenidate Hcl12$164
Alprazolam42$158
Zolpidem Tartrate20$133
Trazodone Hcl17$130
Lamotrigine19$120
Sertraline Hcl21$102

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena$191$36,07013 claims
Almatica Pharma LLCSertraline Hcl$70$10221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,167 psychiatric/mental health providers in Tennessee.

Other psychiatric/mental health in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →